Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms EQUATOR
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

Most Recent Events

  • 01 Mar 2022 Results evaluating the short- and long-term effects of brexpiprazole on patient functioning in schizophrenia using post hoc analysis of short and long term studies published in the Journal of Clinical Psychiatry
  • 31 Jul 2018 According to a Lundbeck A/S media release, the European Commission has approved Rxulti (brexpiprazole) for the treatment of schizophrenia in adults.
  • 01 Jun 2018 According to a Lundbeck A/S media release, Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion on Rxulti (brexpiprazole) for the treatment of schizophrenia in adults. A final decision from the European Commission is expected within 67 days.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top